UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A MALT lymphoma prognostic index

Blood, 2017-09, Vol.130 (12), p.1409-1417

2017

Volltextzugriff (PDF)

Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis

Bone marrow transplantation (Basingstoke), 2021-08, Vol.56 (8), p.1876-1887

2021

Volltextzugriff (PDF)

Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study

Journal of clinical oncology, 2013-02, Vol.31 (5), p.565-572

2013

Volltextzugriff (PDF)

Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.

Breast (Edinburgh), 2024-02, Vol.73, p.103672-103672, Article 103672

2024

Volltextzugriff (PDF)

Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization

Expert opinion on biological therapy, 2014-06, Vol.14 (6), p.757-772

2014

Volltextzugriff (PDF)

Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review

Current oncology (Toronto), 2023-03, Vol.30 (3), p.3494-3499

2023

Volltextzugriff (PDF)

Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1979-1983

2005

Volltextzugriff (PDF)

Disposal of the residual autologous HSC units: Results of a survey carried out two years after the publication of a national policy in Italy

Transfusion and apheresis science, 2018-04, Vol.57 (2), p.197-200

2018

Volltextzugriff (PDF)

Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study

Transplantation and cellular therapy, 2021-03, Vol.27 (3), p.244.e1-244.e8

2021

Volltextzugriff (PDF)

Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study

Journal of clinical oncology, 2010-05, Vol.28 (13), p.2233-2238

2010

Volltextzugriff (PDF)

Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation

Journal of clinical oncology, 2001-08, Vol.19 (16), p.3675-3684

2001

Volltextzugriff (PDF)

Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancer

Seminars in oncology, 2024-10

2024

Volltextzugriff (PDF)

Screening of related donors and peripheral blood stem cell collection practices at different Italian apheresis centres

Blood transfusion = Trasfusione del sangue, 2012-10, Vol.10 (4), p.440-447

2012

Volltextzugriff (PDF)

Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis

Seminars in oncology, 2023-12, Vol.50 (6), p.140-143

2023

Volltextzugriff (PDF)

A Cellular Therapy with Haploidentical Peripheral Hematopoietic STEM CELL Transplantation MAY be a Therapeutic Option in Patients with Relapsed Lymphoma with Chemorefractory Disease

Blood, 2018-11, Vol.132 (Supplement 1), p.2189-2189

2018

Volltextzugriff (PDF)

Case report – Prolonged SARS-CoV-2 positive PCR after resolution of symptoms

Discussion of Clinical Cases, 2020-06, Vol.7 (1), p.1

2020

Volltextzugriff (PDF)

Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research

Clinical cancer research, 2024-03, Vol.30 (6), p.1093-1103

2024

Volltextzugriff (PDF)

Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis

Seminars in oncology, 2023-02, Vol.50 (1-2), p.34-39

2023

Volltextzugriff (PDF)

Midline catheter as effective device in healthy allogeneic donors and patients without an adequate peripheral venous access for HPC collection by apheresis: Preliminary experience at IEO

Transfusion and apheresis science, 2020-06, Vol.59 (3), p.102740-102740, Article 102740

2020

Volltextzugriff (PDF)

Cost comparison of extracorporeal photopheresis technologies at the European Institute of Oncology

Journal of clinical apheresis, 2021-06, Vol.36 (3), p.364-369

2021

Volltextzugriff (PDF)

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

Journal of clinical oncology, 2016-02, Vol.34 (5), p.495-500

2016

Volltextzugriff (PDF)

Plerixafor: what we still have to learn

Expert opinion on biological therapy, 2015-02, Vol.15 (2), p.143-147

2015

Volltextzugriff (PDF)

Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma

Transfusion (Philadelphia, Pa.), 2014-02, Vol.54 (2), p.331-339

2014

Volltextzugriff (PDF)

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity‐score weighted multicenter approach

American journal of hematology, 2017-09, Vol.92 (9), p.E557-E559

2017

Volltextzugriff (PDF)

1 – 25 von 145

Suche als RSS-Feed

Aktive Filter

ThemaRisk Assessment

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(129)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(142)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(91)
Life Sciences & Biomedicine
(70)
Humans
(54)
Male
(37)
Female
(35)
Hematology
(30)
Middle Aged
(29)
Adult
(27)
Oncology
(27)
Aged
(22)
Treatment Outcome
(15)
Physical Sciences
(14)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Retrospective Studies
(10)
Hematopoietic Stem Cell Mobilization - Methods
(8)
Physics
(8)
Technology
(8)
Adolescent
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A MALT lymphoma prognostic index

Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis

Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study

Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.

Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization

Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review

Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy

Disposal of the residual autologous HSC units: Results of a survey carried out two years after the publication of a national policy in Italy

Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study

Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study

Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation

Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancer

Screening of related donors and peripheral blood stem cell collection practices at different Italian apheresis centres

Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis

A Cellular Therapy with Haploidentical Peripheral Hematopoietic STEM CELL Transplantation MAY be a Therapeutic Option in Patients with Relapsed Lymphoma with Chemorefractory Disease

Case report – Prolonged SARS-CoV-2 positive PCR after resolution of symptoms

Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research

Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis

Midline catheter as effective device in healthy allogeneic donors and patients without an adequate peripheral venous access for HPC collection by apheresis: Preliminary experience at IEO

Cost comparison of extracorporeal photopheresis technologies at the European Institute of Oncology

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

Plerixafor: what we still have to learn

Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo

Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity‐score weighted multicenter approach

Aktive Filter

Suchergebnisse filtern